Showing results (51-60 of 176) with videos related to
Sort By:
Pageof 18
Targeted Oncology|June 15, 2014
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b studyIrene Brana, Antonio Calles, Patricia M LoRusso, et al.Journal for Immunotherapy of Cancer|August 4, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trialEmiliano Calvo, Valentina Boni, Olivier Dumas, et al.Investigational New Drugs|December 20, 2022
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumorsVictor Moreno, Ruth Perets, Tamar Peretz-Yablonski, et al.Clinical Colorectal Cancer|November 28, 2002
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II studyEmiliano Calvo, Javier Cortés, Javier Rodríguez, et al.Investigational New Drugs|February 19, 2014
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumorsRamón Salazar, Antonio Calles, Marta Gil, et al.International Journal of Molecular Sciences|April 13, 2024
In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 TherapiesAdrián Sanvicente, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, et al.Cancer Treatment Reviews|January 28, 2024
The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectivesMiriam Dorta-Suárez, Maria de Miguel, Oscar Amor-Carro, et al.European Journal of Cancer (Oxford, England : 1990)|October 3, 2018
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumoursAnas Gazzah, Valentina Boni, Jean-Charles Soria, et al.Pharmaceuticals (Basel, Switzerland)|February 24, 2024
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction StudyIrene Moreno, Tatiana Hernández, Emiliano Calvo, et al.Cancer Metastasis Reviews|July 20, 2010
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populationsEmiliano Calvo, Pablo Maroto, Xavier García del Muro, et al.Pageof 18